Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD34 monoclonal antibody/sirolimus - OrbusNeich

Drug Profile

Anti CD34 monoclonal antibody/sirolimus - OrbusNeich

Alternative Names: Combo Dual Therapy Stent; COMBO Plus Dual Therapy Stent; OrbusNeich Combo Stent™

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OrbusNeich
  • Class Anti-infectives; Ischaemic heart disorder therapies; Macrolides; Monoclonal antibodies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Coronary artery disease

Most Recent Events

  • 26 Sep 2019 Registered for Coronary artery restenosis (Prevention) in Japan (Intracoronary)
  • 25 Oct 2018 Phase-II/III HARMONEE registrational trial is ongoing in Japan and USA (NCT02073565)
  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Coronary artery disease in China (Intracoronary, Implant)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top